These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32139500)

  • 1. Acceptability, adherence and economic analyses of a new clinical pathway for the identification of non-responders to glaucoma eye drops: a prospective observational study.
    Waterman H; Read S; Morgan JE; Gillespie D; Nollett C; Allen D; Weiss M; Anderson P
    Br J Ophthalmol; 2020 Dec; 104(12):1704-1709. PubMed ID: 32139500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol maleate 0.5% fixed combination.
    Inoue K; Okayama R; Higa R; Sawada H; Wakakura M; Tomita G
    J Ocul Pharmacol Ther; 2011 Dec; 27(6):581-7. PubMed ID: 22011049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing the effectiveness of selective laser trabeculoplasty with topical medication as initial treatment (the Glaucoma Initial Treatment Study): study protocol for a randomised controlled trial.
    Lamoureux EL; Mcintosh R; Constantinou M; Fenwick EK; Xie J; Casson R; Finkelstein E; Goldberg I; Healey P; Thomas R; Ang GS; Pesudovs K; Crowston J
    Trials; 2015 Sep; 16():406. PubMed ID: 26362541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma.
    Rouland JF; Traverso CE; Stalmans I; Fekih LE; Delval L; Renault D; Baudouin C;
    Br J Ophthalmol; 2013 Feb; 97(2):196-200. PubMed ID: 23203707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular surface status in glaucoma and ocular hypertension patients with existing corneal disorders switched from latanoprost 0.005% to tafluprost 0.0015%: comparison of two prostaglandin analogues with different concentrations of benzalkonium chloride.
    Wong TT; Aung T; Ho CL
    Clin Exp Ophthalmol; 2018 Dec; 46(9):1028-1034. PubMed ID: 29802759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The physical properties of generic latanoprost ophthalmic solutions are not identical.
    Kolko M; Koch Jensen P
    Acta Ophthalmol; 2017 Jun; 95(4):370-373. PubMed ID: 28229536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study.
    Weinreb RN; Ong T; Scassellati Sforzolini B; Vittitow JL; Singh K; Kaufman PL;
    Br J Ophthalmol; 2015 Jun; 99(6):738-45. PubMed ID: 25488946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Affecting Adherence to Topical Glaucoma Therapy: A Quantitative and Qualitative Pilot Study Analysis in Sydney, Australia.
    Spencer SKR; Shulruf B; McPherson ZE; Zhang H; Lee MB; Francis IC; Bank A; Coroneo MT; Agar A
    Ophthalmol Glaucoma; 2019; 2(2):86-93. PubMed ID: 32672609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of medication adherence to topical glaucoma therapy.
    Dreer LE; Girkin C; Mansberger SL
    J Glaucoma; 2012; 21(4):234-40. PubMed ID: 21623223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients.
    Okeke CO; Quigley HA; Jampel HD; Ying GS; Plyler RJ; Jiang Y; Friedman DS
    Ophthalmology; 2009 Dec; 116(12):2286-93. PubMed ID: 19815286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of a short version of the glaucoma medication self-efficacy questionnaire.
    Sleath B; Blalock SJ; Stone JL; Skinner AC; Covert D; Muir K; Robin AL
    Br J Ophthalmol; 2012 Feb; 96(2):258-62. PubMed ID: 21610264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Readability of prescription labels and medication recall in a population of tertiary referral glaucoma patients.
    O'Hare F; Jeganathan VS; Rokahr CG; Rogers SL; Crowston JG
    Clin Exp Ophthalmol; 2009 Dec; 37(9):849-54. PubMed ID: 20092593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension.
    Sinha S; Lee D; Kolomeyer NN; Myers JS; Razeghinejad R
    Expert Opin Pharmacother; 2020 Jan; 21(1):39-45. PubMed ID: 31663782
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of different dose schedules of latanoprost on intraocular pressure and pupil size in the glaucomatous Beagle.
    Gelatt KN; MacKay EO
    Vet Ophthalmol; 2001 Dec; 4(4):283-8. PubMed ID: 11906665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nationwide survey of factors influencing adherence to ocular hypotensive eyedrops in Japan.
    Tsumura T; Kashiwagi K; Suzuki Y; Yoshikawa K; Suzumura H; Maeda T; Takeda R; Saito H; Araie M
    Int Ophthalmol; 2019 Feb; 39(2):375-383. PubMed ID: 29330811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension.
    Aung T; Chew PT; Yip CC; Chan YH; See JL; Khng CG; Hoh ST; Ng LH; Lee HM
    Am J Ophthalmol; 2001 May; 131(5):636-42. PubMed ID: 11336940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating eye drop instillation technique in glaucoma patients.
    Gupta R; Patil B; Shah BM; Bali SJ; Mishra SK; Dada T
    J Glaucoma; 2012 Mar; 21(3):189-92. PubMed ID: 21336146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma.
    Friedman DS; Okeke CO; Jampel HD; Ying GS; Plyler RJ; Jiang Y; Quigley HA
    Ophthalmology; 2009 Jun; 116(6):1097-105. PubMed ID: 19376591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective laser trabeculoplasty versus drops for newly diagnosed ocular hypertension and glaucoma: the LiGHT RCT.
    Gazzard G; Konstantakopoulou E; Garway-Heath D; Garg A; Vickerstaff V; Hunter R; Ambler G; Bunce C; Wormald R; Nathwani N; Barton K; Rubin G; Morris S; Buszewicz M
    Health Technol Assess; 2019 Jun; 23(31):1-102. PubMed ID: 31264958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effect of latanoprost/timolol fixed combination in patients with glaucoma or ocular hypertension: a prospective, observational, noninterventional study.
    Schwenn O; Heckmann B; Guzy C; Miller PJ
    BMC Ophthalmol; 2010 Sep; 10():21. PubMed ID: 20825668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.